| Cell Robotics International, Inc. | |||
| Proposed Ticker: | CRII | 2715 Broadbent Parkway N.E. | |
| Exchange: | NASDAQ-Small Cap Market | Albuquerque, NM 87107 | |
| Industry: | Wholesale (SIC Code 5049) | (505) 343-1131 | |
| # of Employees: | 15 | ||
| Type of Shares: | Common Shares | Filing Date: | 11/24/97 | |
| U.S. Shares Filed: | 2,000,000 | Filing Range: | $4.00 - $5.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $9,000,000 | |
| Primary Shares: | 2,000,000 | Expenses: | $550,000 | |
| Secondary Shares: | 0 | Shares Out After: | 7,222,414 |
| Manager | Tier | Phone |
| Paulson Investment Company, Inc. | Lead Manager | (503) 243-6028 |
| Cohig & Associates Inc. | Co-manager | (303) 694-0295 |
| Issuer's Law Firm: | Neuman & Drennen, LLC |
| Bank's Law Firm: | Morse, Zelnick, Rose & Lander, LLP |
| Auditor: | KPMG Peat Marwick |
| Registrar/Transfer Agent: | Corporate Stock Transfer, Inc. CO |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 9/30/97 | 9/30/96 | 9/30/97 | ||
| Revenue: | $0.66 | $0.83 | $0.59 | Assets: | $1.78 |
| Net Income: | -$1.54 | -$1.82 | -$1.08 | Curr Assets: | $1.50 |
| EPS: | -$0.37 | -$0.36 | -$0.28 | Liabilities: | $0.73 |
| Prior EPS: | -$0.66 | -$1.80 | -$0.92 | Curr Liabilities: | $0.73 |
| Cash Flow/Oper: | -$1.32 | $0.67 | $2.43 | Equity: | $1.06 |
| Cash Flow/Fin: | $2.44 | -$0.03 | -$0.12 | Cash: | $0.56 |
| Cash Flow/Inv: | -$0.14 | -$0.03 | Working Cap: | $0.77 | |
| Business Description |
| The company has developed, and is preparing to manufacture, market and sell, a number of sophisticated medical laser products. The "Lasette-TM-," a compact lightweight, portable skin perforator, has been designed to permit nearly painless sampling of capillary blood in both clinical and home settings. The "RevitaLase-TM-," is a modularly-designed laser system for dermatological use, which incorporates the laser in the hand-piece. Its design allows for suitable for specific applications, driven by a common base unit containing computer controls, power supply and cooling system. The company intends to market the RevitaLase-TM- with its Erbium:YAG laser head by establishing an OEM relationship with a major manufacturer of CO2 and other medical laser systems for the aesthetic market, to be supplemented by direct selling methods by the company, except that in the United States the IVF Workstation-TM- will not be offered for laser-assisted hatching until after FDA clearance is obtained. |
| Competition |
| The industry in which the company competes with its medical laser products is characterized by rapidly evolving technology and intense competition. Many companies of all sizes, including both large organizations as well as several specialized medical laser products companies are engaged in activities similar to that of the company. In addition, colleges universities, governmental agencies and other public and private research institutions will continue to conduct research and to protect technologies that they have developed, some of which will be directly competitive with that of the company. Many of the company's competitors have substantially greater financial, research and development, human and other resources than the company. The company believes it has certain technological advantages in producing the compact, low-cost laser design in the Lasette-TM- and the RevitaLase-TM-. However, the company's cost advantage is dependent in part upon its ability to maintain its relationship with New Technology Enterprise Center, its Russian associate, the supplier of the crystals used in the manufacture of its lasers, the continuation of which is in doubt due to current unresolved disputes between the company and NTEC. In addition, the company has experienced quality or supply problems with its Russian supplier, either of which, if not remedied, could necessitate it changing the source of supply. Alternative sources of supply for the crystals, while available, would increase the production cost of the company's product and reduce its competitive advantage. |
| Business Plan |
| The company has developed a business strategy to provide a line of technologically-advanced proprietary medical laser products for both clinical and consumer markets. The company's goal is to provide advanced medical laser products that provide superior safety, efficacy and comfort at competitive prices. The key components of this business strategy include: (I) Exploit Proprietary Technology, (ii) Develop Market Recognition, (iii) Establish Exclusive Distribution Channels and (iv) Rapidly Expand Capacity to Assemble Products. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund marketing and sales, to acquire fixed assets, to hire additional marketing and manufacturing personnel, to fund further research and development and for working capital and for general corporate purposes. |
| Name of Shareholder | % Owned Before | % Owned After |
| Richard S. Hall | 11.90% | 8.60% |
| Ronald K. Lohrding | 8.80% | 6.40% |
| Mitsui Engineering & Shipbuilding Co., Ltd. | 7.80% | 5.70% |
| Officer Name | Title | Age |
| Michael Wolf | Chief Engineer | 55 |
| Jean Scharf | Chief Financial Officer and Controller | 35 |
| Richard Zigweid | Manufacturing Manager | 49 |
| Dr. Ronald K. Lohrding | President, Chief Executive Officer and Chairman of the Board | 56 |
| Dr. Larry Keenan | Product Manager, CR Workstation | 50 |
| Dr. Jerome Conia | Product Manager, IVF Workstation-TM- | 37 |
| David Costello | Product Manager, Lasette-TM- | 42 |
| Connie White | Regulatory Affairs and Quality Manager | 43 |
| Craig T. Rogers | Vice-President of Investor Relations, Secretary, Treasurer and Director | 35 |
| Travis Lee | Vice-President of Sales and Marketing | 38 |
| Additional Underwriter Compensation |
| Warrant to purchase 200,000 shares/units at a nominal price. |
| Exercise price of $5.40 for 4 year(s), 1 year(s) from . |